tumor lysis syndrome

Accelerated venetoclax ramp-up for R/R CLL 2:28
Accelerated venetoclax ramp-up for R/R CLL
Matthew Davids • 5 Dec 2020
SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCL 3:18
SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCL
Constantine Tam • 10 Dec 2020
TLS in patients with CLL treated with venetoclax 1:34
TLS in patients with CLL treated with venetoclax
William Wierda • 1 Dec 2020
Obinutuzumab +/- bendamustine debulking prior to venetoclax in CLL 2:36
Obinutuzumab +/- bendamustine debulking prior to venetoclax in CLL
Jeff Sharman • 7 Dec 2019
Predicting TLS in venetoclax-treated CLL patients 1:43
Predicting TLS in venetoclax-treated CLL patients
Anthony Mato • 22 Sep 2019
U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation 1:37
U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation
Anthony Mato • 22 Sep 2019
Liso-Cel in CLL 4:47
Liso-Cel in CLL
Tanya Siddiqi • 14 Jun 2019
MRD negativity as a treatment endpoint in CLL 1:52
MRD negativity as a treatment endpoint in CLL
Arnon Kater • 14 Jun 2018
MURANO update: MRD, biological subsets & safety analysis 2:43
MURANO update: MRD, biological subsets & safety analysis
John Seymour • 14 Jun 2018
MURANO study: exciting times in CLL 2:06
MURANO study: exciting times in CLL
George Follows • 9 Dec 2017
Retrospective multicenter analysis of venetoclax-treated CLL patients 3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato • 9 Dec 2017
Primary analysis of MURANO study data for R/R CLL 4:01
Primary analysis of MURANO study data for R/R CLL
John Seymour • 9 Dec 2017
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL 8:06
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL
Peter Hillmen
Managing and predicting TLS in CLL patients 1:00
Managing and predicting TLS in CLL patients
Peter Hillmen • 27 Mar 2017
The power of venetoclax 5:52
The power of venetoclax
Claire Dearden • 29 Mar 2017
BCL2 inhibition and CLL: the role of venetoclax 3:09
BCL2 inhibition and CLL: the role of venetoclax
Peter Hillmen • 29 Mar 2017
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals